

1 **A u-shape association of serum uric acid with gout**
2 **in US adults**

3 Yan Xinmiao¹, Sun Taolan¹, Zhao Zixuan¹, Luo Yanrong², Zhao Hanbing², Zhao Han², Li Miaojing^{2*}

4 ¹ Chengdu Medical College, Chengdu, Sichuan, 610500, PR China

5 ² Department of health management, College of health and intelligent engineering, Chengdu,

6 Sichuan, 610500, PR China

7 *Corresponding author

8 E-mail: limiaojing@aliyun.com (LMJ)

9

10 **Abstract**

11 **Background**

12 Serum uric acid (SUA) level is the strongest determinant of gout, and the
13 relationship between hyperuricemia and gout has been found. However, the
14 association between the across-full range of SUA level and gout also
15 remains uncertain. We aimed to investigate the trend across an across-full
16 range of SUA level and gout in the general population.

17 **Materials and Methods**

18 This study included 4,738 US adults from The National Health and Nutrition
19 Examination Survey (NHANES). A generalized additive model was used to
20 fit the non-linear trend between SUA level and gout.

21 **Results**

22 2,209 males and 2,469 females were included in our study, with the age
23 range of 20~80 years. The range of SUA level was from 0.8 to 15.1 mg/dL.
24 About 5.9% of participants had gout. There was a U-shape association
25 between SUA level and gout in univariable GAM (EDF = 3.881, $p < 0.001$)
26 and multivariable GAM (EDF = 3.795, $p < 0.001$). The lowest risk of gout
27 was observed in participants with SUA level of 5-6mg/dL. We evaluated the
28 trend of SUA level with gout by gender. Both males and females with high
29 SUA level have a high prevalence of gout. Male have a high prevalence of
30 gout with low SUA level. The SUA level and prevalence of gout support a
31 U-shape in males, while females show a linear shape.

32 **Conclusion**

33 This study showed that low as well as high SUA are associated with gout.

34 Hypouricemia is a candidate predictor of gout in US adults.

35

36

37

38 **Introduction**

39 According to the Global Burden of Disease (GBD) 2017, there were 41.2
40 million (95% *UI*: 36.7 million~46.1 million) adults with gout worldwide. In
41 2017, the age standardized point prevalence estimate and the increase of
42 age-standardized point prevalence estimate of gout in the United States
43 ranked among the top three in the world[1]. A prospective cohort study
44 showed that the all-cause standardized mortality in gout patients was 2.21
45 (95% *CI*: 1.68-2.74)[2]. In addition, gout is associated with several diseases,
46 including joint pain, chronic kidney disease (CKD), hypertension, type 2
47 diabetes, dyslipidemia, etc[3], which has effect on the life [4],
48 productivity[5, 6] and health-related quality of life (HRQOL)[7, 8]. High
49 uric acid (hyperuricemia) is the strongest determinant of gout, and many
50 studies have proved the existence of this association [9-11]. SUA level can
51 be maintained at a certain target level through urate-lowering treatment
52 (ULT), effectively reducing the incidence of gout[12, 13]. Although some
53 research on high SUA level and gout has been reported, the underlying
54 association between across-full range of SUA level and gout is still
55 uncertain. There is currently a lack of consensus regarding the optimal range
56 for SUA levels and few studies have evaluated the prevalence of gout across
57 the full range of SUA level in the US adults.

58 An analysis of the time of first gout occurrences using Cox proportional

59 hazards model in a cohort study in Japan showed that the HR of
60 asymptomatic hyperuricemia ($5.0 < \text{SUA} \leq 6.0$ mg/dL) of ULT was the
61 lowest, at 0.45 (95% *CI*: 0.27-0.76), compared with untreated subjects (SUA
62 ≥ 8.0 mg/dL). In subjects with asymptomatic hyperuricemia, controlling
63 SUA can reduce or eliminate gout occurrences[14]. In another Mendelian
64 randomization study, it presented convincing evidence that the increased
65 risk of gout was associated with high SUA level ($n=71\ 501$, *OR*: 5.84; 95%
66 *CI*: 4.56-7.49, $p<0.01$)[15]. Meanwhile, studies have shown that before the
67 age of 65 years, male have a fourfold greater incidence of gout than female
68 [10, 16-18]. However, the risk of gout development in patients with
69 hypouricemia has not yet been clarified. D'silva et al reported that the risk
70 of all-cause mortality risk among US males with SUA level <4 mg/dL was
71 about 30% higher[19]. This indicates that it is necessary to further study
72 the relationship between SUA level and gout and its impact on males and
73 females.
74 Therefore, based on the National Health and Nutrition Examination Survey
75 (NHANES), we explore the trend between SUA level and gout.

76

77 **Materials and methods**

78

79 **Data Source and Study Population**

80 The National Health and Nutrition Examination Survey (NHANES) is a

81 unique source of national data on the health and nutritional status of the US
82 population, collecting data through interviews, standard exams, and
83 biospecimen collection. NHANES adopts a stratified and multi-stage
84 sampling design, and the survey population involves each county in US.
85 Each year, about 5,000 persons in 15 counties are selected to conduct a
86 nationally representative sample survey. Informed consent was obtained
87 from all participants.

88

89 NHANES 2017-2018 dataset was used in this study. There was a total of
90 9,254 participants being enrolled. Participants with age ≥ 20 years old were
91 included for analysis. However, we excluded participants that had no uric
92 acid data ($n=3353$), no gout data ($n=987$), missing in covariates variables
93 ($n=176$). Eventually, 4,738 participants were included in our study and the
94 distribution of the number of participants with different value of uric acid
95 are shown in Fig 1.

96

97 **Fig 1. Distribution of the number of participants with different value of uric**

98 **acid.**

99

100 **Variable measurements**

101 Socio-demographic factors and modifiable risk factor of gout were included
102 in this study. We obtained the data of these variables from seven parts of

103 following: “Demographic Data”, “Standard Biochemistry Profile”,
104 “Alcohol Use”, “Blood Pressure & Cholesterol”, “Smoking - Cigarette Use”,
105 “Kidney Conditions - Urology” and “Medical Conditions”.

106

107 **Gout**

108 Gout was self-reported data. Whether participants have gout was defined
109 using the question, “Has a doctor or other health professional ever told you
110 that you had gout?”.

111

112 **Serum Uric acid level**

113 In this study, we used the SUA level in the laboratory data as interested
114 independent variable and recorded as a continuous variable. The detail
115 process of laboratory data measurement was described in the NHANES
116 database official website.

117

118 **Covariates**

119 In this study, the covariates included gender, age, education, marriage, race,
120 alcohol drinking, smoking, hypertension, diabetes and kidney disease. Age
121 was divided into three groups: 20~39, 40~59, and 60 years or older.
122 Education level was categorized into primary and secondary, high school,
123 above high school. Marriage was grouped into four categories: married,
124 widowed divorced or separated, never married, living with a partner. Race

125 was divided into six categories: Mexican American, other Hispanic, non-
126 Hispanic White, non-Hispanic Black, non-Hispanic Asian, other race -
127 including Multi-Racial. Alcohol drinking was classified as never, almost
128 every day, 3 to 4 times a week, 1 to 2 times a week, 1 to 3 times a month,
129 and 1 to 11 times a year. Smoking was defined as "at least 100 cigarettes in
130 a lifetime". Diagnosis of hypertension, diabetes and kidney disease were
131 determined with questions: "Have you ever been told by a doctor or health
132 care provider that you have high blood pressure, diabetes or problems with
133 high blood sugar, weak or failing kidneys".

134

135 **Statistical Analysis**

136 Descriptive statistics on participants' characteristics were stratified by
137 whether they had gout. Chi-squared test was utilized to determine the
138 association between categorical variable. The generalized additive model
139 (GAM) was used to assess the potential trend between SUA level and gout.
140 The GAM approach is an extension of the generalized linear model (GLM),
141 which is a generalized linear model with linear predictions involving sums
142 of covariates (Wood, 2011). The smoothness of the model terms was
143 estimated using penalized cubic regression splines for fitting. The model
144 selection included the Akaike information criterion (AIC), the difference
145 between EDF and ref. df, with lower values considered to be better-fitting
146 models. As our response variable types were categorical variables, we chose

147 “Logit” as our link function, and it was considered that the fixed effects
148 were estimated by Restrictive maximum likelihood (REML).
149 (<http://doi.org/10.1080/01621459.2016.1180986>)

150 Non-linear relationship of SUA level with gout was assessed through GAM.
151 In our analysis, we fit three GAM models to NHANES data. The three
152 models used gout (yes/no) as a binary response.

153

	Response	Predictor
Model 1	Gout	Smooth (SUA level)
Model 2	Gout	Smooth (SUA level) +Covariates
Model 3	Gout (Group by Gender)	Smooth (SUA level) +Covariates

154

155 The reported values of effective degree of freedom (EDF) demonstrate the
156 degree of curvature of the smooth. “EDF=1” means a linear pattern of the
157 relationship. “EDF >1” is the sign of a more complex relationship between
158 SUA level and gout. The Ref. df is close to the EDF when the GAM is
159 reasonably fitted. The best explanation for the P-value of the smooth part
160 is that a line parallel to the X-axis cannot pass through the 95% confidence
161 interval of the curve.

162 SAS 9.4 (Statistical analysis system) was used for data cleaning and
163 statistical description. GAM in our analysis was using the "mgcv" package
164 (version 1.8–28) in R statistical software (version 4.1.1). The statistical
165 tests were two-sided, and the significance level was set at 0.05.

166

167 Results

168 Characteristics of participants

169 A total of 4,738 eligible participants (2,209 males and 2,469 females) were
 170 included in our study, with the age range of 20~80 years. About 48.12%
 171 were male, and 56.61% educated in above high school. A total of 50.65%
 172 of the sample were married. The range of SUA level was from 0.8 to 15.1
 173 mg/dL. About 5.9% of participants had gout. All factors had significant
 174 statistical differences except education, details are shown in Table 1.

175 **Table 1. characteristics of the participants in NHANES according to gout**

	<i>n</i> (%)	Gout		<i>P</i>
		Yes , <i>n</i> =280	No , <i>n</i> =4458	
Uric acid (mg/dL)		6.35±1.79	5.41±1.46	<0.001
Gender				
Male	2280(48.12)	193(8.46)	2087(91.54)	<0.001
Female	2458(51.88)	87(3.54)	2371(96.46)	
Age				
20-39years	1444(30.48)	13(0.90)	1431(99.10)	<0.001
40-59years	1515(31.98)	74(4.88)	1441(95.12)	
Over 60 years	1779(37.55)	193(10.85)	1586(89.15)	
Education				
Primary and secondary	389(8.21)	20(5.14)	369(94.86)	0.780
High	1667(35.18)	98(5.88)	1569(94.12)	
Above high	2682(56.61)	162(6.04)	2520(93.96)	
Marital Status				
Married	2400(50.65)	153(6.38)	2247(93.63)	<0.001

Widowed, Divorced or Separated	1068(22.54)	84(7.87)	984(92.13)	
Never married	845(17.83)	23(2.72)	822(97.28)	
Living with partner	425(8.97)	20(4.71)	405(95.29)	
Race				
Mexican American	651(13.74)	21(3.23)	630(96.77)	0.002
Other Hispanic	444(9.37)	16(3.60)	428(96.40)	
Non-Hispanic White	1656(34.95)	116(7.00)	1540(93.00)	
Non-Hispanic Black	1080(22.79)	67(6.20)	1013(93.80)	
Non-Hispanic Asian	670(14.14)	48(7.16)	622(92.84)	
Other Race - Including Multi-Racial	237(5.00)	12(5.06)	225(94.94)	
Alcohol				
Never drink	927(23.20)	73(7.87)	854(92.13)	0.001
Every day or almost every day	272(6.81)	25(9.19)	247(90.81)	
3-4 times a week	243(6.08)	18(7.41)	225(92.59)	
1-2 times a week	603(15.09)	34(5.64)	569(94.36)	
1-3 times a month	841(21.05)	39(4.64)	802(95.36)	
1-11 times last year	1110(27.78)	47(4.23)	1063(95.77)	
Diabetes				
Yes	737(15.56)	100(13.57)	637(86.43)	<0.001
No	3853(81.32)	166(4.31)	3687(95.69)	
Borderline	148(3.12)	14(9.46)	134(90.54)	
Kidney disease				
Yes	188(3.97)	42(22.34)	146(77.66)	<0.001
No	4550(96.03)	238(5.23)	4312(94.77)	
Hypertension				
Yes	1790(37.78)	185(10.34)	1605(89.66)	<0.001
No	2948(62.22)	95(3.22)	2853(96.78)	

Smoking				
Yes	1967(41.52)	160(8.13)	1807(91.87)	<0.001
No	2771(58.48)	120(4.33)	2651(95.67)	

176

177 **Model 1: Gout and serum uric acid(univariable)**

178 Model 1 used gout (Yes/No) as a binary response. The results of non-linear
 179 parameters of GAM were presented in Table 2. A smoothing spline function
 180 of SUA level as a univariable predictor was shown in Fig 2($EDF= 3.881$,
 181 $p<0.001$). The prevalence of gout increased with the increase of SUA level
 182 at the SUA level of 5-10 mg/dL. When the SUA level was extreme, the trend
 183 was relatively flat.

184

185 **Fig 2. Figure of estimated smoothing spline function of prevalence of gout (The**
 186 **reference group is participants without gout) with 95% confidence band for the**
 187 **univariable generalized additive model 1.**

188

189 **Table 2. the smooth function of gout measured by the GAM (model1)**

Smooth terms	EDF	Ref.df	c^2	P
Reference (Yes)				
Gout (No)	3.881	4.875	123.4	<0.001

190

191 **Model 2: Gout and serum uric acid(multivariable)**

192 Model 2, which was a multivariable version of model 1 but further adjusted
 193 for covariates was shown in Fig 3. A non-linear shape was found between

194 SUA level and gout ($EDF=3.795$, $p<0.001$), and the predicted smooth
195 association of SUA level and gout including the 95% confidence intervals,
196 was shown in Fig 3. The figure showed a U-shape association of SUA level
197 and the prevalence of gout in multivariable GAM models. The lowest
198 prevalence observed was SUA level of 5-6mg/dL. SUA level had the
199 strongest effect on gout at the SUA level which was lower than 5 mg/dL or
200 at 6-11 mg/dL. While SUA level exceed 11 mg/dL, the prevalence of gout
201 began to decline slowly. The results of non-linear parameters of GAM were
202 presented in Table 3, the parameter section results were detailed in S1 Table.

203

204 **Fig 3. Figure of estimated smoothing spline function of prevalence of gout (The**
205 **reference group is participants without gout) with 95% confidence band for the**
206 **multivariable generalized additive model 2 adjusted for gender, age, marital**
207 **status, education, race, smoking, alcohol, diabetes, kidney disease and**
208 **hypertension.**

209

210 **Table 3. the smooth function of gout measured by the GAM (model2)**

Smooth terms	EDF	Ref.df	c^2	P
Reference (Yes)				
Gout (No)	3.795	4.789	37.67	<0.001

211

212 **Model 3: Gout and serum uric acid (Group by gender)**

213 Furthermore, the effect of SUA level on gout in male and female was
 214 evaluated in model 3. The significant result indicates a non-linear shape
 215 between SUA level and gout in male ($EDF=1.873$, $p<0.001$), which was
 216 similar to the trend of entire population. However, the non-linear shape
 217 between SUA level and gout was not identified in female ($EDF=1.001$,
 218 $p=0.087$). The Fig 4 showed the smoothing shapes are different in male and
 219 female, which a significant U-shape association of SUA level and the gout
 220 in male and a linear in female. The lowest risk is observed in those SUA
 221 level 5~6mg/dL in male and low or high SUA level will increase the risk of
 222 gout. The results of non-linear parameters of GAM were presented in Table
 223 4, the parameter section results were detailed in S2.1 and S2.2 Table.

224

225 **Fig 4. Figures of estimated smoothing spline function of prevalence of gout level**
 226 **(Group by gender, and the reference group is participants without gout) with**
 227 **95% confidence band for the multivariable generalized additive model 3. And a**
 228 **for male, b for female.**

229

230 **Table 4. Association of SUA level and gout measured by the GAM(Group**
 231 **by gender)(model3)**

Smooth terms	EDF	Ref.df	c^2	P
Reference (Yes)				
Spline (Uric Acid): Male	1.873	1.984	16.45	<0.001
Spline (Uric Acid): Female	1.001	1.002	2.931	0.087

232

233

234 **Discussion**

235 As the final product of purine metabolism, SUA has many effects on the
236 human body. Previous studies found that increased SUA levels were
237 associated with gout, diabetes[20], hypertension[21], obesity[22], and
238 cancer[23, 24]. However, few studies have assessed the relationship
239 between across-full range of SUA level and gout. This study constructs a
240 generalized additivity model to explore the potential relationship between
241 SUA level and gout based on US adults.

242 In our study, the *EDF* of univariate and multivariate models adjusted for
243 age, sex, education and other important confounding factors were all greater
244 than 3, indicating a non-linear relationship between SUA level and gout and
245 a U-shape association was demonstrated in the figure. The results of our
246 study showed a high prevalence of gout with high SUA level in US adults,
247 but the prevalence of gout begins to decline slowly when SUA level is above
248 11 mg/dL. Males with low SUA level also have a high prevalence of gout.
249 The association between SUA level and prevalence of gout support a U-
250 shape in males, while females show a linear shape.

251 A previous study already confirmed that SUA level higher than 6mg/dL can
252 increase the risk of gout, which is in agreement with our result[25].

253 Secondly, the prevalence of gout decreased when SUA level was higher than
254 11 mg/dL. We speculated that the high level of SUA in this part of the

255 population may be caused by other diseases or drugs[26]. Furthermore, low
256 SUA level was also associated with gout. A sudden decrease in SUA may
257 also trigger a gout attack by dissolution of monosodium urate (MSU) from
258 tophi[26]. In addition, hypouricemia has been shown to increase the risk of
259 worsening kidney function. In the CARES trial, all-cause and
260 cardiovascular mortality rates were higher in the febuxostat group than in
261 the allopurinol group, despite lower SUA levels in gout patients taking
262 febuxostat[27]. Some previous studies also showed that SUA was u-shape
263 associated with all-cause mortality[28, 29] and nephropathy, and SUA
264 reduction treatment was associated with higher mortality[30]. One study
265 showed that SUA level between 5-6mg/dL is reasonable[31], which is
266 consistent with our finding. Ames et al hypothesized that SUA may act as a
267 protective factor against aging and cancer caused by oxidants and free
268 radicals due to its antioxidant function[32]. Therefore, SUA should be
269 maintained in a certain range, above or below this range will increase the
270 probability of developing gout. The different trends between males and
271 females are because estrogen has a urination effect on females, which can
272 reduce the risk of gout. However, with elevated SUA level after menopause,
273 the proportion of older female with gout may increase and gender
274 differences decrease[17, 33].

275 Studies have shown that the occurrence of gout is related to kidney
276 disease[9, 34, 35]. SUA level in vivo is closely related to renal function.

277 About two-thirds of uric acid is excreted in urine[36], and uric acid is
278 filtered by glomerulus and reabsorbed by proximal tubules, with a normal
279 excretion rate of 10%[37]. A prospective cohort study showed a U-shape
280 association between SUA and loss of renal function in healthy subjects[38].
281 Therefore, the relationship between SUA and kidney disease may be a
282 potential cause for the existence of this U-shape association that was found
283 in our study, but further studies are needed to prove this. Because gout is
284 considered a disease that primarily affects male, it may be underrecognized
285 in female even after menopause. There were clear differences in risk
286 between male and female.

287 There are also limitations in our research. Firstly, our research is an
288 observational study, which cannot infer a causal relationship between SUA
289 level and gout. Secondly, many variables in our study are self-reported.
290 Despite these limitations, our study also has advantages. Firstly, this study
291 used a smoothing curve to explore the non-linear trend between SUA level
292 and gout. Secondly, we assessed the risk of gout at all SUA level in the
293 ordinary population, taking into account both low SUA level and high SUA
294 level. Finally, we assessed the trend of prevalence of gout with SUA level
295 in both males and females.

296

297 **Conclusion**

298 In our study, there is a U-shape between SUA level and gout. High SUA
299 level or low SUA level are both risk factors for gout. Further researches are
300 needed to trace people with low SUA level and clarify the
301 pathophysiological mechanisms between low SUA level and gout to reduce
302 the likelihood of gout occurring.

303

304 **Author Contributions**

305 YXM and STL were responsible for data extraction, data analyses, model
306 construction and the manuscript writing. LMJ selected the topic, directs the
307 writing, improves the revision. ZZX provided specific knowledge, carried
308 out the literature research. ZHB, ZH, LYR coordinated and managed the
309 operation of the project and the implementation of the project. All authors
310 read and approved the final manuscript.

311

312


313

314 **References**


- 315 1. Safiri S, Kolahi A-A, Cross M, Carson-Chahhoud K, Hoy D, Almasi-Hashiani A, et al.
316 Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors
317 for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease
318 Study 2017. *Arthritis Rheumatol.* 2020;72(11):1916-27. doi: 10.1002/art.41404. PubMed PMID:
319 32755051.
- 320 2. Disveld IJM, Zoakman S, Jansen TLTA, Rongen GA, Kienhorst LBE, Janssens HJEM, et al.
321 Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and
322 infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort
323 study. *Clin Rheumatol.* 2019;38(5):1385-91. doi: 10.1007/s10067-019-04520-6. PubMed PMID:
324 30929152.
- 325 3. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on
326 prevalence and treatment options. *BMC Med.* 2017;15(1):123. doi: 10.1186/s12916-017-0890-9.
327 PubMed PMID: 28669352.
- 328 4. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control
329 study. *Rheumatology (Oxford).* 2007;46(9):1441-4. PubMed PMID: 17586863.
- 330 5. Edwards NL, Sundry JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due
331 to flares in patients with chronic gout refractory to conventional therapy. *J Med Econ.* 2011;14(1):10-5.
332 doi: 10.3111/13696998.2010.540874. PubMed PMID: 21138339.
- 333 6. Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact
334 of gout on work absence and productivity. *Value Health.* 2007;10(4):231-7. PubMed PMID: 17645677.
- 335 7. Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, et al. The disutility of
336 chronic gout. *Qual Life Res.* 2008;17(5):815-22. doi: 10.1007/s11136-008-9355-0. PubMed PMID:
337 18500578.
- 338 8. Singh JA. Racial and gender disparities among patients with gout. *Curr Rheumatol Rep.*
339 2013;15(2):307. doi: 10.1007/s11926-012-0307-x. PubMed PMID: 23315156.
- 340 9. Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence,
341 incidence and risk factors. *Nat Rev Rheumatol.* 2015;11(11):649-62. doi: 10.1038/nrrheum.2015.91.
342 PubMed PMID: 26150127.
- 343 10. Richette P, Bardin T. Gout. *Lancet.* 2010;375(9711):318-28. doi: 10.1016/S0140-
344 6736(09)60883-7. PubMed PMID: 19692116.
- 345 11. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. *Lancet.* 2021;397(10287):1843-55. doi:
346 10.1016/S0140-6736(21)00569-9. PubMed PMID: 33798500.
- 347 12. Hainer BL, Matheson E, Wilkes RT. Diagnosis, treatment, and prevention of gout. *Am Fam*
348 *Physician.* 2014;90(12):831-6. PubMed PMID: 25591183.
- 349 13. Perez-Ruiz F. Treating to target: a strategy to cure gout. *Rheumatology (Oxford).* 2009;48
350 Suppl 2. doi: 10.1093/rheumatology/kep087. PubMed PMID: 19447780.
- 351 14. Koto R, Nakajima A, Horiuchi H, Yamanaka H. Serum uric acid control for prevention of gout
352 flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance
353 claims and medical check-up data in Japan. *Ann Rheum Dis.* 2021;80(11):1483-90. doi:
354 10.1136/annrheumdis-2021-220439. PubMed PMID: 34158371.
- 355 15. Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, et al. Causal Assessment of Serum

-
- 356 Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. *J Am Coll*
357 *Cardiol.* 2016;67(4):407-16. doi: 10.1016/j.jacc.2015.10.086. PubMed PMID: 26821629.
- 358 16. Ruoff G, Edwards NL. Overview of Serum Uric Acid Treatment Targets in Gout: Why Less
359 Than 6 mg/dL? *Postgrad Med.* 2016;128(7):706-15. doi: 10.1080/00325481.2016.1221732. PubMed
360 PMID: 27558643.
- 361 17. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. *Arthritis*
362 *Res Ther.* 2006;8 Suppl 1:S2. PubMed PMID: 16820041.
- 363 18. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and
364 hyperuricemia over 10 years among older adults in a managed care population. *J Rheumatol.*
365 2004;31(8):1582-7. PubMed PMID: 15290739.
- 366 19. D'Silva KM, Yokose C, Lu N, McCormick N, Lee H, Zhang Y, et al. Hypouricemia and
367 Mortality Risk in the US General Population. *Arthritis Care Res (Hoboken).* 2021;73(8):1171-9. doi:
368 10.1002/acr.24476. PubMed PMID: 33026684.
- 369 20. van der Schaft N, Brahimaj A, Wen K-X, Franco OH, Dehghan A. The association between
370 serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: The Rotterdam Study.
371 *PLoS One.* 2017;12(6):e0179482. doi: 10.1371/journal.pone.0179482. PubMed PMID: 28632742.
- 372 21. Zheng R, Yang T, Chen Q, Chen C, Mao Y. Serum Uric Acid Concentrations Can Predict
373 Hypertension: A Longitudinal Population-Based Epidemiological Study. *Horm Metab Res.*
374 2017;49(11):873-9. doi: 10.1055/s-0043-119129. PubMed PMID: 28922678.
- 375 22. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of
376 Obesity: a Longitudinal Population-Based Epidemiological Study. *Clin Lab.* 2017;63(10):1581-7. doi:
377 10.7754/Clin.Lab.2017.170311. PubMed PMID: 29035437.
- 378 23. Yue C-F, Feng P-N, Yao Z-R, Yu X-G, Lin W-B, Qian Y-M, et al. High serum uric acid
379 concentration predicts poor survival in patients with breast cancer. *Clin Chim Acta.* 2017;473:160-5. doi:
380 10.1016/j.cca.2017.08.027. PubMed PMID: 28844462.
- 381 24. Shin H-S, Lee H-R, Lee D-C, Shim J-Y, Cho K-H, Suh S-Y. Uric acid as a prognostic factor
382 for survival time: a prospective cohort study of terminally ill cancer patients. *J Pain Symptom Manage.*
383 2006;31(6):493-501. PubMed PMID: 16793489.
- 384 25. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout.
385 *Adv Ther.* 2015;32(1):31-41. doi: 10.1007/s12325-014-0175-z. PubMed PMID: 25533440.
- 386 26. Zhang W-Z. Why Does Hyperuricemia Not Necessarily Induce Gout? *Biomolecules.*
387 2021;11(2). doi: 10.3390/biom11020280. PubMed PMID: 33672821.
- 388 27. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular
389 Safety of Febuxostat or Allopurinol in Patients with Gout. *N Engl J Med.* 2018;378(13):1200-10. doi:
390 10.1056/NEJMoa1710895. PubMed PMID: 29527974.
- 391 28. Hu L, Hu G, Xu BP, Zhu L, Zhou W, Wang T, et al. U-Shaped Association of Serum Uric
392 Acid With All-Cause and Cause-Specific Mortality in US Adults: A Cohort Study. *J Clin Endocrinol*
393 *Metab.* 2020;105(1). doi: 10.1210/clinem/dgz068. PubMed PMID: 31650159.
- 394 29. Stotz M, Szkandera J, Seidel J, Stojakovic T, Samonigg H, Reitz D, et al. Evaluation of uric
395 acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. *PLoS One.*
396 2014;9(8):e104730. doi: 10.1371/journal.pone.0104730. PubMed PMID: 25133546.
- 397 30. Odden MC, Amadu A-R, Smit E, Lo L, Peralta CA. Uric acid levels, kidney function, and
398 cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES)
399 1988-1994 and 1999-2002. *Am J Kidney Dis.* 2014;64(4):550-7. doi: 10.1053/j.ajkd.2014.04.024.


-
- 400 PubMed PMID: 24906981.
- 401 31. Bellomo G, Selvi A. Uric Acid: The Lower the Better? *Contrib Nephrol.* 2018;192:69-76. doi:
402 10.1159/000484280. PubMed PMID: 29393097.
- 403 32. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in
404 humans against oxidant- and radical-caused aging and cancer: a hypothesis. *Proc Natl Acad Sci U S A.*
405 1981;78(11):6858-62. PubMed PMID: 6947260.
- 406 33. Doherty M. New insights into the epidemiology of gout. *Rheumatology (Oxford).* 2009;48
407 Suppl 2:ii2-ii8. doi: 10.1093/rheumatology/kep086. PubMed PMID: 19447779.
- 408 34. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med.*
409 2008;359(17):1811-21. doi: 10.1056/NEJMra0800885. PubMed PMID: 18946066.
- 410 35. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence,
411 treatment patterns and risk factors. *Nat Rev Rheumatol.* 2020;16(7):380-90. doi: 10.1038/s41584-020-
412 0441-1. PubMed PMID: 32541923.
- 413 36. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties.
414 *Adv Chronic Kidney Dis.* 2012;19(6):358-71. doi: 10.1053/j.ackd.2012.07.009. PubMed PMID:
415 23089270.
- 416 37. Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. *Pediatr Nephrol.* 2014;29(6).
417 doi: 10.1007/s00467-013-2549-x. PubMed PMID: 23824181.
- 418 38. Kanda E, Muneyuki T, Kanno Y, Suwa K, Nakajima K. Uric acid level has a U-shaped
419 association with loss of kidney function in healthy people: a prospective cohort study. *PLoS One.*
420 2015;10(2):e0118031. doi: 10.1371/journal.pone.0118031. PubMed PMID: 25658588.
- 421
- 422



Figure




Figure




Figure

a.



b.



Figure